---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-064744"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-06-03T20:25:25+00:00"
generated_at: "2026-06-03T20:51:28.260196+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics CFO Matthew Szot leaves; CEO Quang Pham takes interim CFO role

## Summary
- CFO Matthew K. Szot mutually agreed to step down effective May 28, 2026.
- CEO Quang X. Pham appointed interim CFO and interim principal accounting officer.
- Company is conducting a search for a permanent CFO to replace Szot.
- Severance includes $365,806 severance, $237,903 FY2026 target bonus, and accelerated option vesting.

## SEC filing metadata
- accession: 0001213900-26-064744
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-06-03T20:25:25+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/ea0293458-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-064744
- JSON: https://secwatch.observer/filing/0001213900-26-064744.json
- Plain text: https://secwatch.observer/filing/0001213900-26-064744.txt

## Key facts
- Executive change
  Matthew K. Szot changed role as Chief Financial Officer at Cadrenal Therapeutics, Inc..
  - Action: mutually agreed to his transition from the role
  - Role: Chief Financial Officer
  source text: On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm
- Executive change
  Quang X. Pham was appointed as interim Chief Financial Officer and interim Principal Accounting Officer at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer and interim Principal Accounting Officer
  source text: Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.